Vaccines: past, present and future

被引：350

作者：

Plotkin, SA ^{[1
]}

机构：

[1] Univ Penn, Doylestown, PA 18901 USA

来源：

NATURE MEDICINE | 2005年 / 11卷 / 04期

关键词：

D O I：

10.1038/nm1209

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines.

引用

收藏

页码：S5 / S11

页数：7

相关论文

共 87 条

[21] Cancer vaccines: Between the idea and the reality [J].

Finn, OJ .

NATURE REVIEWS IMMUNOLOGY, 2003, 3 (08) :630-641

[22] New pertussis vaccination strategies beyond infancy:: Recommendations by the global pertussis initiative [J].

Forsyth, KD ;

Campins-Marti, M ;

Caro, J ;

Cherry, JD ;

Greenberg, D ;

Guiso, N ;

Heininger, U ;

Schellekens, J ;

Tan, T ;

von König, CHW ;

Plotkin, S .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (12) :1802-1809

[23] Immunotherapy for Alzheimer's disease [J].

Gelinas, DS ;

DaSilva, K ;

Fenili, D ;

George-Hyslop, PS ;

McLaurin, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14657-14662

[24]

Glenn Gregory M, 2003, Expert Rev Vaccines, V2, P253, DOI 10.1586/14760584.2.2.253

[25] Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates [J].

Guirakhoo, F ;

Pugachev, K ;

Zhang, Z ;

Myers, G ;

Levenbook, I ;

Draper, K ;

Lang, J ;

Ocran, S ;

Mitchell, F ;

Parsons, M ;

Brown, N ;

Brandler, S ;

Fournier, C ;

Barrere, B ;

Rizvi, F ;

Travassos, A ;

Nichols, R ;

Trent, D ;

Monath, T .

JOURNAL OF VIROLOGY, 2004, 78 (09) :4761-4775

[26] Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia [J].

Hallez, S ;

Simon, P ;

Maudoux, F ;

Doyen, J ;

Noël, JC ;

Beliard, A ;

Capelle, X ;

Buxant, F ;

Fayt, I ;

Lagrost, AC ;

Hubert, P ;

Gerday, C ;

Burny, A ;

Boniver, J ;

Foidart, JM ;

Delvenne, P ;

Jacobs, N .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (07) :642-650

[27] Transcutaneous immunization: T cell responses and boosting of existing immunity [J].

Hammond, SA ;

Walwender, D ;

Alving, CR ;

Glenn, GM .

VACCINE, 2001, 19 (17-19) :2701-2707

[28] Vaccines for the prevention of diseases caused by potential bioweapons [J].

Hassani, M ;

Patel, MC ;

Pirofski, LA .

CLINICAL IMMUNOLOGY, 2004, 111 (01) :1-15

[29] Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination [J].

Hoft, DF ;

Leonardi, C ;

Milligan, T ;

Nahass, GT ;

Kemp, B ;

Cook, S ;

Tennant, J ;

Carey, M .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (04) :785-790

[30] Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines [J].

Hohlfeid, R ;

Wekerle, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14599-14606

← 1 2 3 4 5 6 7 8 9 →